#USA #San Francisco #Antengene #ADCs #TCEs

Antengene Showcases Groundbreaking Advances at JPM Conference

Antengene Corporation Limited has made headlines by presenting at the esteemed 44th Annual J.P. Morgan Healthcare Conference in San Francisco. The international biotech innovator, known for its commitment to developing first-in-class therapeutics, shared crucial updates on clinical trials and their forward-looking strategy.

Key Highlights of Clinical Developments

Antengene's presentations focused primarily on their leading clinical asset, ATG-022, an antibody-drug conjugate (ADC) targeting CLDN18.2. As of late December 2025, the results from the Phase I/II CLINCH study are promising:

• - In the 2.4 mg/kg dose cohort: 40% of patients with moderate to high CLDN18.2 expression showed an objective response rate (ORR), while a staggering 90% experienced disease control.
• - In the 1.8 mg/kg cohort: The ORR reached 46.7%, showcasing the potential for this therapy across different patient profiles. Notably, one patient from each dose group achieved a complete response (CR).

These results underline ATG-022's impressive anti-tumor efficacy, laying the groundwork for future studies and combinations with therapies like checkpoint inhibitors (CPIs) and chemotherapy.

Potential Beyond Gastrointestinal Tumors

For the first time, Antengene revealed positive clinical signals for ATG-022's efficacy in treating non-gastrointestinal tumors, with a 22.2% ORR from a small cohort. This discovery could potentially redefine the scope of treatable cancers, extending far beyond gastrointestinal types.

Moving Forward with Development

Antengene is not resting on its laurels; plans are underway to further advance ATG-022 through multiple lines of gastric cancer therapy. They are conducting complementary studies in China and Australia, focusing on various combinations that target CLDN18.2 levels across a wide spectrum of gastric cancer.

Next-Generation ADCs and Innovative TCEs

Antengene is excited about their next-generation products, particularly:

• - ATG-125: A B7-H3 x PD-L1 bispecific ADC that combines the strengths of ADCs with immune-oncology therapies. It’s designed to overcome immune suppression and is expected to have superior efficacy compared to single-target therapies.
• - AnTenGager™ Platform: A proprietary T cell engager technology tailored for low-expressing targets, designed to enhance efficacy while minimizing side effects such as cytokine release syndromes.

Multiple Pipeline Programs

Antengene's innovative pipeline includes several other investigational products:

• - ATG-201: Targeting CD19 in B cell-related diseases, with positive preclinical results showing minimal side effects.
• - ATG-106: The first-in-class TCE for treating ovarian and kidney cancers, with an IND submission anticipated shortly.
• - ATG-207: Targeted for T cell-mediated autoimmune diseases, preclinical data will be unveiled at a significant scientific gathering in 2026.

Antengene's approach to pioneering biotherapeutics in oncology and autoimmune conditions reflects an ambitious vision aligned with addressing significant unmet medical needs. With a robust pipeline, they have already secured 32 IND approvals, marking themselves as a force to be reckoned with in the biopharmaceutical landscape.

Conclusion

Antengene's recent presentation at the JPM Healthcare Conference highlights their commitment not only to advancing therapeutic options for cancer but also to innovative solutions for autoimmune diseases. With a promising pipeline and a focused strategy on utilizing ADCs and TCEs, Antengene is poised for significant developments in the biotechnology arena. Watch this space for more as they continue to pave the way for groundbreaking treatments on a global scale.